A restructuring of staff within the US FDA to strengthen the Oncology Center of Excellence (OCE) is one of the primary changes that advocates want to see in the agency's intercenter institute.
At an OCE listening session March 15, several external stakeholders commented to FDA staff that they would like to see...








